Last reviewed · How we verify
Minnebro (esaxerenone)
At a glance
| Generic name | esaxerenone |
|---|---|
| Sponsor | Daiichi Sankyo |
| Target | Mineralocorticoid receptor |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetic nephropathy
- Hypertension
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects (PHASE2)
- A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment (PHASE2)
- Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension (PHASE3)
- The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers (PHASE1)
- Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension (NA)
- Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria (PHASE3)
- Study of CS-3150 in Patients With Essential Hypertension (PHASE3)
- Study of CS-3150 in Patients With Severe Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minnebro CI brief — competitive landscape report
- Minnebro updates RSS · CI watch RSS
- Daiichi Sankyo portfolio CI